Monte Rosa Therapeutics (GLUE)
Develops molecular glue degrader medicines across oncology, immunology, and inflammation.
$11.85
vs last close−0.75 (−5.94%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 108.53% | 92.59M shares | |
|---|---|---|---|
| 202 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.68% | 7.40M shares | |
| 9 holders · as of Jul 17, 2026 | |||
| Strategic holders | 4.78% | 4.08M shares | |
| 1 holder · as of Oct 30, 2024 | |||
| Adds to | 121.99% | ||
85.31M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 121.99%; nothing is left for Other.
13F, as of Jun 30, 2026
202 holders · 92.59M shares · 31 new positions · 111 increased · 60 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Price T Rowe Associates Inc /MD/ | 8.86M | 10.39% | +2.14M | Aug 14, 2026 |
| Nea Management Company, LLC | 7.69M | 9.02% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.84M | 8.02% | +1.21M | Aug 7, 2026 |
| TCG Crossover Management, LLC | 4.62M | 5.42% | 0 | Aug 14, 2026 |
| Vestal Point Capital, LP | 4.60M | 5.39% | +996.5K | Aug 14, 2026 |
| BVF Inc/IL | 4.46M | 5.23% | 0 | Aug 14, 2026 |
| Baker Bros. Advisors LP | 4.35M | 5.09% | 0 | Aug 14, 2026 |
| State Street Corp | 3.73M | 4.37% | +377.4K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 9.99% | 8.88M | 13G | May 15, 2026 |
| Adam Goulburn | 8.10% | 6.51M | 13G | Apr 22, 2026 |
| Nea 17 GP, LLCincl. Paul Walker, Mohamad H. Makhzoumi +9 more | 7.90% | 6.69M | 13D | Jul 6, 2026 |
| T. Rowe Price Associates, Inc. | 7.50% | 4.64M | 13G | Nov 14, 2025 |
| BlackRock, Inc. | 6.30% | 3.84M | 13G | Feb 4, 2025 |
| Suvretta Capital Management, LLC | 5.50% | 3.36M | 13G | Apr 16, 2025 |
| Vestal Point Capital, LP | 5.40% | 4.60M | 13G | Aug 14, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 16, 2026 | Markus Warmuthdirector, officer: President & CEO | Sale | 9,500 | $23.18 | 585,038 |
| Jul 15, 2026 | Jennifer Champouxofficer: Chief Operating Officer | Sale | 4,351 | $23.38 | 62,371 |
| Jul 6, 2026 | Sharon Townsonofficer: Chief Scientific Officer | Sale · 2 lots | 6,000 | $23.31 | 67,845 |
| Jun 30, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 5,407 | $24.50 | 60,612 |
| Jun 29, 2026 | Anthony M. Manningdirector | Sale | 10,000 | $23.11 | 0 |
| Jun 29, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 6,000 | $22.95 | 59,992 |
| Jun 23, 2026 | Sharon Townsonofficer: Chief Scientific Officer | Sale | 3,000 | $20.00 | 67,845 |
| Jun 23, 2026 | Jennifer Champouxofficer: Chief Operating Officer | Sale | 2,175 | $20.00 | 62,371 |
| Jun 24, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 30,000 | $21.42 | 59,992 |
| Jun 23, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 11,845 | $20.22 | 59,992 |
House and Senate disclosures
Not reported.